Pan-India healthcare products distributor linking 3,300+ manufacturers to 1,05,300+ pharmacies and hospitals.
Reported
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 1,940 | +38.2% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 5.0 | +1.4 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 52.0 | +73.3% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
| Return on equity | 7.57 | +1.3 pts | Trailing twelve months | TTM to Jun 2026 | Adjusted profit attributable to owners ÷ average owners’ equity. |
| Free cash flow margin | 0.42 | +2.1 pts | Fiscal year | FY ending Mar 2026 | (Operating cash flow − fixed-asset purchases + disposals) ÷ revenue. |
| Revenue growth (YoY) | 31.93 | −0.6 pts | Trailing twelve months | TTM to Jun 2026 | Revenue change against the same period one year earlier. |
Guidance
9 of 12 judged targets kept · 14 open · verdicts reflect calls analysed to Q1 FY27.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| Long-term Return on Equity (ROE) | 20% plus in 2-3 years | Q4 FY24 | Q1 FY27 ROE was reported at 20.4%, meeting the original long-term target of '20% plus' well ahead of the previously diluted timeline. | Achieved |
| FY25 Revenue Growth | 35% to 40% revenue growth in FY '25 | Q4 FY24 | This promise pertains to a past financial year (FY25) and was not addressed. | Missed |
| Long-term EBITDA Margin | close to 5% beyond FY26 | Q4 FY25 | Achieved 5.0% EBITDA margin in Q1 FY27, hitting the long-term target in the first quarter beyond FY26. This demonstrates strong progress towards sustaining this level. | On Track |
3 of Entero Healthcare Solutions Limited's 26 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 23 more targets are in the full ledger.
Claimed
Qualified
Price
1Y: ₹1,087.5 on 24 Oct 2025 → ₹1,578.2. High ₹1,898.4 (7 Sept 2026), low ₹949.2 (29 Dec 2025).
Overview
Based on the company's own presentations, annual report and earnings calls.
Entero Healthcare Solutions is a healthcare products supply-chain and distribution company operating in India's pharmaceutical and, more recently, MedTech (IVD, cardiology, orthopedics) markets. It sources from pharmaceutical and healthcare product manufacturers and moves goods through central warehousing and pan-India redistribution to retail pharmacies and hospitals, earning distribution margins on the goods it handles. Beyond product fulfilment, it also offers manufacturers demand-generation services such as deploying medical representatives and managing marketing/channel strategy. The company operates as a single reportable wholesale-distribution segment and has grown its footprint substantially through an active acquisition programme alongside organic expansion.
close before → close after
The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.
Guidance
9 of 12 judged targets kept · 14 open · verdicts reflect calls analysed to Q1 FY27.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| Long-term Return on Equity (ROE) | 20% plus in 2-3 years | Q4 FY24 | Q1 FY27 ROE was reported at 20.4%, meeting the original long-term target of '20% plus' well ahead of the previously diluted timeline. | Achieved |
| FY25 Revenue Growth | 35% to 40% revenue growth in FY '25 | Q4 FY24 | This promise pertains to a past financial year (FY25) and was not addressed. | Missed |
| Long-term EBITDA Margin | close to 5% beyond FY26 | Q4 FY25 | Achieved 5.0% EBITDA margin in Q1 FY27, hitting the long-term target in the first quarter beyond FY26. This demonstrates strong progress towards sustaining this level. | On Track |
Claimed
Qualified
The full ledger
A free account opens 5 company ledgers a month. All 26 tracked commitments, with each call’s wording and source.
Call summaries
Entero Healthcare Solutions Limited Q1 FY27
Entero Healthcare Solutions reported a strong Q1 FY27, with significant revenue growth and margin expansion, achieving its full-year EBITDA margin guidance early. The company demonstrated improved capital efficiency with doubled ROCE and ROE. Strategic focus remains on organic growth, consolidation, and leveraging the MedTech segment, with no major new acquisitions in the quarter.
Read the full callEntero Healthcar Q4 FY26
Entero Healthcare Solutions reported strong Q4 and full year FY26 results, driven by robust organic growth, strategic acquisitions, and margin expansion. The company achieved a 4.5% EBITDA margin in Q4 and 4% for the full year, along with significant PAT growth. Management provided an optimistic FY27 guidance, targeting 23% revenue growth and 5% EBITDA margins, while focusing on operational efficiencies and MedTech expansion.
Read the full callEntero Healthcar Q3 FY26
Entero Healthcare Solutions delivered a strong Q3 FY26, with revenue growing 26% YoY and EBITDA up 36% YoY, driven by robust organic growth and strategic MedTech acquisitions. The company demonstrated improved operational efficiency, reflected in better working capital days and positive operating cash flow. Management expressed confidence in achieving full-year guidance for both OCF and EBITDA margins, despite the need for significant Q4 performance.
Read the full callEvery analysed call
Fundamentals
Current values with the period they cover; the trend reads across the 6 fiscal years held (Mar 2021 to Mar 2026).
Financials
Net profit, year on year: +73% (quarter to jun 2026 against jun 2025).
| Line item | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 1,301 | 1,359 | 1,339 | 1,404 | 1,571 | 1,707 | 1,910 | 1,940 |
| Expenses | 1,258 | 1,309 | 1,290 | 1,354 | 1,509 | 1,639 | 1,824 | 1,844 |
| Operating profit | 42 | 50 | 49 | 50 | 62 | 68 | 86 | 97 |
| Operating margin | 3.3% | 3.7% | 3.6% | 3.6% | 4.0% | 4.0% | 4.5% | 5.0% |
| Other income | 11 | 8 | 7 | 6 | 5 | -4 | 4 | 3 |
| Interest | 11 | 10 | 10 | 11 | 12 | 14 | 17 | 21 |
| Depreciation | 7 | 8 | 8 | 9 | 10 | 10 | 15 | 12 |
| Profit before tax | 35 | 39 | 37 | 36 | 45 | 40 | 58 | 67 |
| Tax rate | 25.0% | 25.0% | 16.0% | 17.0% | 18.0% | 16.0% | 22.0% | 22.0% |
| Net profit | 26 | 29 | 31 | 30 | 37 | 34 | 45 | 52 |
| EPS (₹ per share) | 5.43 | 5.85 | 5.90 | 6.39 | 7.26 | 6.35 | 6.44 | 8.77 |
| Line item | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Sales | 3,922 | 5,096 | 6,592 |
| Expenses | 3,810 | 4,924 | 6,326 |
| Operating profit | 113 | 171 | 266 |
| Other income | 14 | 39 | 11 |
| Interest | 65 | 41 | 54 |
| Depreciation | 25 | 30 | 44 |
| Profit before tax | 36 | 138 | 179 |
| Net profit | 39 | 107 | 146 |
| Line item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sept 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Equity capital | 4 | 4 | 43 | 44 | 44 | 44 |
| Reserves | -62 | -73 | 1,595 | 1,681 | 1,723 | 1,645 |
| Borrowings | 974 | 1,101 | 338 | 385 | 443 | 677 |
| Other liabilities | 210 | 275 | 369 | 593 | 642 | 1,234 |
| Total liabilities | 1,125 | 1,308 | 2,345 | 2,703 | 2,851 | 3,600 |
| Fixed assets | 262 | 268 | 289 | 559 | 627 | 958 |
| Capital work in progress | 1 | 0 | 0 | 0 | 0 | 2 |
| Investments | 0 | 0 | 0 | 58 | 67 | 130 |
| Other assets | 863 | 1,040 | 2,056 | 2,085 | 2,158 | 2,510 |
| Total assets | 1,125 | 1,308 | 2,345 | 2,703 | 2,851 | 3,600 |
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Cash from operations | -69 | -35 | -45 | -37 | -77 | 96 |
| Cash from investing | -31 | -162 | -49 | -704 | 232 | -302 |
| Cash from financing | 89 | 211 | 73 | 863 | -74 | 124 |
| Net cash flow | -11 | 14 | -21 | 122 | 82 | -82 |
| Free cash flow | -78 | -45 | -51 | -41 | -87 | 29 |
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Debtor days | 50 | 54 | 57 | 57 | 59 | 67 |
| Inventory days | 54 | 49 | 41 | 43 | 52 | 52 |
| Days payable | 22 | 22 | 25 | 24 | 31 | 45 |
| Cash conversion cycle | 82 | 81 | 73 | 77 | 80 | 74 |
| Working capital days | 54 | 41 | 32 | 48 | 65 | 35 |
| Return on capital employed | 1.0% | 1.0% | 5.0% | 7.0% | 9.0% | 10.0% |
| Dividend payout | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
To justify its price of ₹1578, this stock must grow earnings at 27% every year for 7 years. Our analysis caps realistic growth at ~93%. At that growth it is worth ₹26225 — upside of 1562%.
Ownership
Promoters hold 52.40% as of Sept 2026; institutions added 7.08 pts since Jun 2026.
since Jun 2026
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
The same filing shows 2 holders trimming and 2 off the list — both are in the register beside this.
Named in the Sep 2026 filing
Every holder of Entero Healthcare Solutions Limited above SEBI's 1% disclosure line, and what changed since Jun 2026.
| Holder | Stake | Change |
|---|---|---|
| 38.00% | unchanged | |
| 9.26% | unchanged | |
| 5.15% | unchanged | |
| Mutual fund | 3.19% | newly disclosed |
| Mutual fund | 3.19% | newly disclosed |
| 3.05% | −7.40 pp | |
| AIF | 3.03% | newly disclosed |
| Mutual fund | 2.40% | +0.28 pp |
| AIF | 1.53% | −0.42 pp |
| AIF | 1.18% | newly disclosed |
| 1.01% | newly disclosed | |
| Mutual fund | — | off the list |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Filings to Sep 2026
2 new, 0 added, 0 trimmed, 0 sold out — net +13.90 L shares.
| Scheme | Holding | Last month | Held since |
|---|---|---|---|
| HDFC Balanced Advantage Fund HDFC Mutual Fund | ₹202 Cr | new | Sep '26 |
| HDFC Pharma and Healthcare Fund HDFC Mutual Fund | ₹35 Cr | new | Sep '26 |
HDFC, Nippon India and SBI schemes, from their monthly disclosures. Changes are counted in shares, so a price move never looks like buying or selling.
Mutual funds Sep 2026
0 added, 0 trimmed — net +13.90 L shares
Your own record
Free account: one company. Everything above stays public.
Write why you follow Entero Healthcare Solutions Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading
Guides on how to read this kind of business and the numbers that matter.
